High prevalence of hypovitaminosis D in a Swiss rheumatology outpatient population. by Stoll, D. et al.
Original article | Published 27 May 2011, doi:10.4414/smw.2011.13196
Cite this as: Swiss Med Wkly. 2011;141:w13196
High prevalence of hypovitaminosis D in a Swiss
rheumatology outpatient population
Delphine Stolla, Jean Dudlerb, OlivierLamya, Didier Hansa, Alexander Sob, Marc-Antoine Kriega, Bérengère.Aubry-Roziera,b
a Center for Bone Diseases, University Hospital of Lausanne, Switzerland
b Division of Rheumatology, University Hospital of Lausanne, Switzerland
Correspondence:
Delphine Stoll, MD
Center for Bone Diseases
Lausanne University Hospital (CHUV) – DAL
Avenue Pierre Decker 4
CH1011-Lausanne
Switzerland
Delphine.Stoll@chuv.ch
Summary
Vitamin D is important for bone metabolism and neur-
omuscular function. While a routine dosage is often pro-
posed in osteoporotic patients, it is not so evident in rheum-
atology outpatients where it has been shown that the pre-
valence of hypovitaminosis D is high. The aim of the cur-
rent study was to systematically evaluate the vitamin D
status in our outpatient rheumatology population to define
the severity of the problem according to rheumatologic dis-
eases. During November 2009, all patients were offered a
screening test for 25-OH vitamin D levels and categorised
as deficient (<10 µg/l [ng/ml] [25 nmol/l]), insufficient (10
µg/l to 30 µg/l [25 to 75 nmol/l]) or normal (>30 µg/l [75
nmol/l]). A total of 272 patients were included. The mean
25-OH vitamin D level was 21 µg/l (range 1.5 to 45.9).
A total of 20 patients had vitamin D deficiency, 215 pa-
tients had an insufficiency and 37 patients had normal res-
ults. In the group of patients with osteoporosis mean level
of 25-OH vitamin D was 25 µg/l and 31% had normal res-
ults. In patients with inflammatory rheumatic diseases (N
= 219), the mean level of 25-OH vitamin D was 20.5 µg/
l, and only 12% had normal 25-OH vitamin D levels. In
the small group of patients with degenerative disease (N
= 33), the mean level of 25-OH vitamin D was 21.8 µg/l,
and 21% had normal results. Insufficiency and deficiency
were even seen in 38% of the patients who were taking
supplements. These results confirm that hypovitaminosis D
is highly prevalent in an outpatient population of rheum-
atology patients, affecting 86% of subjects. Despite oral
supplementation (taken in 38% of our population), only a
quarter of those on oral supplementation attained normal
values of 25-OH vitamin D.
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Introduction
Vitamin D plays a major role in bone metabolism and
neuromuscular function [1, 2]. Vitamin D deficiency leads
primarily to osteomalacia, but has also been related to non
specific symptoms such as pain and fatigue [3, 4], while
supplementation with vitamin D (and calcium) has been
shown to be effective for lowering the risk of fractures in
patients with osteoporosis [5–9]. There is also increasing
evidence for a much broader role of vitamin D, and an
increasing numbers of studies investigating the effects of
hypovitaminosis D and/or vitamin D supplementation on
different health aspects have recently been published. Vit-
amin D deficiency has been correlated to a higher incidence
of oncologic, cardiovascular and auto-immune diseases, as
well as increased mortality [10–14]. Nevertheless, vitam-
in D deficiency and insufficiency often remain a neglected
problem. Furthermore, there are now controversies about
optimal vitamin D levels and mode of supplementation
[15].
Vitamin D insufficiency has a high prevalence, with a
gradient between regions depending on the latitude and
amount of sunshine [16]. Hypovitaminosis D is highly pre-
valent in Swiss senior citizens, probably secondary to poor
exposure to sunlight and decreased skin production (about
25% of young adults) [17–19]. The few studies among
rheumatology outpatients have also shown a high preval-
ence of hypovitaminosis D [20–22], and systematic screen-
ing and correction of this problem could improve the man-
agement of these patients with chronic diseases at high risk
of osteoporosis and fractures. An improvement in vitam-
in D levels could also improve the prognosis of patients
with other diseases through other mechanisms as vitamin
D levels have been shown to be inversely correlated with
disease activity scores in inflammatory arthritis and sys-
temic lupus erythematosus (SLE) [23–25]. We therefore
systematically evaluated the vitamin D status in our outpa-
tient rheumatology population to gain a better understand-
ing of the severity of the problem in different categories
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of rheumatologic diseases and in relation to a current oral
supplementation of vitamin D. We decided to use a widely
accepted definition of hypovitaminosis D with vitamin D
deficiency defined as a serum level of 25-OH vitamin D
below 10 µg/l (ng/ml) (25 nmol/l) and vitamin D insuffi-
ciency characterised as serum level of 25-OH vitamin D of
10 to 30 µg/l (25 to 75 nmol/l) [26, 27].
Methods
Study design and subjects
During one month (November 2009), all physicians con-
sulting at our Rheumatology Outpatient Clinic of Lausanne
University Hospital (latitude 46.52°N) were suggested to
offer a blood screening test to evaluate 25-OH vitamin D
levels in all their patients. 25-OH vitamin D levels were de-
termined using the radio-immunologic assay with extrac-
tion (25-hydroxyvitamin D 125I RIA Kit, DiaSorin®): the
first step involves rapid extraction of 25-OH vitamin D and
other hydroxylated metabolites from serum with acetoni-
trile. Following extraction, the treated sample is then as-
sayed using an equilibrium RIA procedure based on an an-
tibody with specificity to 25-OH vitamin D.
Results were classified as followed: deficiency of 25-OH
vitamin D for levels <10 µg/l (25 nmol/l), insufficiency of
25-OH vitamin D for results between 10 µg/l to 30 µg/l (25
to 75 nmol/l) and a normal level of 25-OH vitamin D for
results above 30 µg/l (>75 nmol/l).
Data on the use of daily oral vitamin D3 and calcium sup-
plementation or a single high dose of oral or intramuscular
vitamin D3 in the last 6 months were systematically collec-
ted, and patients were categorised into three non exclusive
categories of rheumatologic diseases: inflammatory rheum-
atologic disease (IRD, including mainly rheumatoid arth-
ritis, spondyloarthropathies and systemic lupus), degener-
ative disease (DD, including mainly chronic low back pain)
and osteoporosis (OP, with or without fracture).
Statistical analysis
Student unpaired t-test were done for body mass index
(BMI), age and 25-OH vitamin D level comparisons
between groups.
Chi squared tests were performed for comparison of pre-
valence of hypovitaminosis D and vitamin D supplementa-
tion in different populations. Significance was reached with
a p value <0.05. Statistical analyses were performed using
Stata 8.1 software, College Station, TX, USA.
Results
During the study period, 292 out of 784 attending patients
(37%) had their level of 25-OH vitamin D determined.
Many patients were not included because they did not get
the blood test since many physicians forgot to offer the test
to their patients. We excluded 20 patients who had received
a single dose of 300’000 IU of vitamin D3 within the last 6
months, and only the 272 remaining patients were used for
the analysis.
Vitamin D levels (table 1)
The mean 25-OH vitamin D level was 21 µg/l (range 1.5
to 45.9). True vitamin D deficiency was fairly rare found
in only 20 patients (7%), whereas an insufficiency was the
majority with 215 patients (79%) falling within this cat-
egory. Only 37 patients (14%) had normal results.
25-OH vitamin D levels were not correlated to age or sex,
with similar figures for the various categories of 25-OH
vitamin D levels. The BMI was significantly higher in pa-
tients with an insufficiency compared with patients with
normal results in our cohort.
Effects of vitamin D supplementation (table 1) (fig. 1)
Of the 272 patients, 104 (38%) were on daily oral supple-
mentation of calcium and vitamin D3 (Calcium 500mg and
vitamin D3 400 IU once or twice a day). A total of four
(4%) of them still had a deficiency, 74 (71%) had an in-
sufficiency and only 26 (25%) had normal results, com-
pared to the 168 patients not receiving any supplementation
where 16 (10%) had a deficiency, 141 (84%) had an insuf-
ficiency and 11 (6%) had a normal 25-OH vitamin D level.
Supplementation did somewhat improve the figures, with
a significantly higher prevalence of normal results and a
lower prevalence of insufficiency (p <0.05). The difference
of prevalence of vitamin D deficiency did not reach stat-
istical significance (p = 0.081), probably due to the small
number of patients in this category.
Figure 1
All patients: effects of vitamin D3 supplementation.
Figure 2
Underlying pathologies: effects of vitamin D3 supplementation.
Circles : black : daily vitamin D3, grey : no supplementation
Def + Insuff: Deficiency + Insufficiency, IRD: Inflammatory
Rheumatic Disease, OP: Osteoporosis, DD: Degenerative Disease
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Effects of underlying pathologies (table 2) (fig. 2)
Of these 272 patients, 219 had an inflammatory rheumat-
ologic disease, 48 consulted for osteoporosis and 33 had a
diagnosis of a degenerative rheumatologic pathology.
As expected, patients’ ages were significantly different
between the three groups of diseases, with patients with
OP being the oldest (mean age 67.7 (range 26.5 to 88.4)),
and the patients with IRD (mean age 50.4 (range 17.7 to
88.4)) significantly younger, even compared to DD patients
(mean age 56.4 (range 17.4 to 85.4)) (p <0.05).
In the small group of OP patients, the mean level of 25-OH
vitamin D was the highest with a mean of 25 µg/l (range
1.5 to 45.9), significantly higher than in patients with IRD
(p <0.05); an observation certainly explained by the high
percentage of patients on oral daily supplementation of cal-
cium and vitamin D3 (40 patients or 83%). Nevertheless,
3 patients still had deficient levels and 30 had insufficient
levels of 25-OH vitamin D, an observation not completely
explained by supplementation.
In the main group of younger IRD patients (44% rheum-
atoid arthritis, 34% spondylarthropathies, 4% systemic
lupus, 28% others), the mean level of 25-OH vitamin D
was surprisingly low to 20.5 µg/l (range 4.3 to 45.9), with
only 26 patients with normal results (12%). A total of 19
had a deficiency and 174 an insufficiency. Again this ob-
servation is only partly explained by the low number of pa-
tients on oral daily supplementation (76 patients or 35%)
with a mean level of 24.3 µg/l (range 8.3 to 45.9) for the
supplemented group, compared to 18.5 µg/l (range 4.3 to
44) for the non-supplemented group.
In the last group of DD, the mean level of 25-OH vitamin
D was 21.8 µg/l (12.1–40.8). None of the patients had a de-
ficiency, 26 had an insufficiency and 7 had normal results,
while 9 patients (27%) were on oral daily supplementation.
Discussion
The current study has many limitations. It was a simple
cross-sectional study and less than 40% of the patients at-
tending our clinic had their levels of vitamin D determined.
Nevertheless, involvement in the study appeared to be dir-
ectly related to the need of blood drawing for another pur-
pose, and is unlikely to reflect a systematic bias. Data on
compliance with supplementation, as well as on sun expos-
ure and calcium and vitamin D3 intake in the diet were also
of very limited quality and did not allow us to draw any
conclusion from them. However, this is a true population-
based study probably reflecting the reality of our current
practice with all its incertitude, but also with very strong
messages about the prevalence of hypovitaminosis D in a
Swiss rheumatologic population and the value of simple
daily oral supplementation.
Hypovitaminosis D was highly prevalent in our population
of rheumatology patients (86%) and certainly under recog-
nised. Most patients (79%) had 25-OH vitamin D levels
values within the range of what we defined as being an
insufficiency, but with still 7% having levels defined as a
true deficiency. As the testing was done in autumn with
the residual effect of the summer sunshine on vitamin D
(storage) levels [28–30], we could have expected better res-
ults. Possible explanations are the lack of sufficient sun-
shine in Switzerland, even in summer, or sun avoidance of
older patients (osteoporosis) or patients with photosensit-
ivity (inflammatory diseases). However, patients were re-
cruited within a region (Lake Geneva coast) with one of the
highest yearly relative sunshine durations, while true cases
of photosensitivity with sun avoidance were exceptional in
the present population, and our results are probably valid
for most Western Europe countries.
Age, sex and BMI did not predict hypovitaminosis D in
our population. Oral supplementation was the only variable
that did influence the prevalence of hypovitaminosis to
some extent. Supplementation with 400 to 800 IU of vitam-
in D3 was relatively frequent (38%) in our population, and
the proportion of patients with normal results was signi-
ficantly higher in those taking supplementation, with 70%
of patients with normal results already being prescribed or-
al daily supplementation of vitamin D3 at the time of the
dosage. However, only a quarter of patients on oral daily
supplementation of calcium and vitamin D3 had a normal
Table 1: 25-OH vitamin D levels.
Number of patients Mean 25-OH vitamin D level (µg/l) Women Age
(years)
BMI
(kg/m²)
Vitamin D3
Supplement
All patients 272 21 (1.5–45.9) 71% 52.6 25.9 38%
Deficiency
(<10 µg/l)
20 7.9 (1.5–9.9) 70% 49.6 24.9 20%
Insufficiency
(10–30 µg/l)
215 19.8 (10.2–29.6) 70% 52.5 26.4 34%
Normal
(>30 µg/l)
37 35.4 (30–45.9) 76% 55 23.4 70%
BMI: Body Mass Index
Table 2: Effects of underlying pathologies.
Number of patients Mean 25-OH vitamin D level (µg/l) Women Age
(years)
BMI
(kg/m²)
Vitamin D3
Supplement
All patients 272 21 (1.5–45.9) 71% 52.6 25.9 38%
IRD 219 20.5 (4.3–45.9) 70% 50.4 # 26 35%
OP 48 25 (1.5–45.9)∞ 79% 67.7 # 25 83%
DD 33 21.8 (12.1–40.8) 70% 56.4 # 27.6 27%
# compared between disease groups: p <0.05
∞ compared with IRD: p = 0.0003
BMI: Body Mass Index, IRD: Inflammatory Rheumatic Disease, OP: Osteoporosis, DD: Degenerative Disease
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value of 25-OH vitamin D; a fact probably mainly related
to poor adherence [31], although insufficient supplementa-
tion is another option [32].
Vitamin D is of course essential for bone and neuromus-
cular health. However, it also has pleiotropic effects on
other tissues and functions. As it’s true physiopathological
importance remains unclear, [1], the high prevalence of
hypovitaminosis D in our younger population of inflam-
matory diseases is of concern as vitamin D levels have
been shown to be correlated with disease activity scores in
early inflammatory synovitis, rheumatoid arthritis and SLE
[23–25, 33]. The vitamin D receptor is highly concentrated
in T cells and vitamin D analogues have been shown to
markedly suppress animal models of autoimmune diseases
[34]. Vitamin D probably exerts immunomodulatory ef-
fects. There are no specific guidelines for the management
of vitamin D levels in patients with inflammatory diseases,
nor randomised clinical trials on the effects of supplement-
ation on disease activity. Nevertheless as rheumatoid arth-
ritis is by itself an independent risk factor for osteoporotic
fracture it appears reasonable to aim for at least the same
level in this population as in patients with osteoporosis
[35]. Finally, with such prevalence of hypovitaminosis D,
clinical studies are definitively needed to evaluate the im-
pact of supplementation in the various rheumatologic pop-
ulations, in particular with regard to disease activity.
Sufficient levels of 25-OH vitamin D are historically
defined as a level sufficient to prevent an increase of para-
thyroid hormone (PTH) levels, and the reference of 31 µg/l
(78 nmol/l) is often suggested despite the fact that this cut-
off is certainly different for each individual [16, 36]. The
International Osteoporosis Foundation (IOF) also suggests
reaching vitamin D levels of 30 µg/l (but no more) to re-
duce the risk of fall and fracture, and it is usually accep-
ted that this level can be reached with a daily intake of
800–1000 IU of vitamin D3 [37, 38]. However, our res-
ults demonstrated that more than 70% of the patients were
below this threshold despite daily oral supplementation.
Therefore, it appears to be very important to motivate our
patients regularly to improve treatment adherence, but also
to check for vitamin D insufficiency in these patients as
there is emerging evidence that usual preparations of vit-
amin D3 and calcium may not be effective at normalising
vitamin D in everyone [39].
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